A novel targeted T-cell modulator, efalizumab, for plaque psoriasis

The drug Raptiva from Genentech may be effective in treating severe psoriasis, according to a study of 597 patients. The drug was given as a subcutaneous injection once a week for up to six months. Between 22% and 28% of the patients had a 75% or greater improvement in symptoms, depending on the dose. Raptiva prevents the activation of T cells that cause psoriasis.